Alkem Laboratories Limited
ALKEM.NS
Cena:
Valuace
41
Růst
23
Zdraví
83
Dokumenty & prezentace
Datum podání
2026
Kvartální
Pl find enclosed unaudited financial results along with LRR for quarter ended 30th June, 2026
14. srp 2026
před 2 měs.
Výroční
Annual Report FY2026
29. čvc 2026
před 3 měs.
Výroční
Pl find enclosed Audited Financial Results along with auditors report for FY ended 31st march 26
28. kvě 2026
před 5 měs.
Kvartální
Pls find enclosed unaudited financial results along with LRR for quarter and nine month ended 31st dec, 25
13. úno 2026
před 8 měs.
2025
Kvartální
Pls find enclosed herewith the Unaudited Financial Results along with the LRR for the quarter and half year ended 30 September, 2025.
13. lis 2025
před 11 měs.
Kvartální
Please find enclosed herewith unaudited financial results along with LRR for quarter ended 30th June, 2025.
12. srp 2025
před 1 r.
Výroční
Annual Report FY2025
21. čvc 2025
před 1 r.
Výroční
Please find enclosed Audited Financial Results along with Auditors Report for FY ended 31st march 25
29. kvě 2025
před 1 r.
Kvartální
PFA unaudited financial results and LRR for quarter and nine months ended 31st Dec, 2024
7. úno 2025
před 2 r.
2024
Kvartální
Please find enclosed herewith the unaudited financial results and limited review report of the Company for the quarter and half year ended 30th Sept, 24.
13. lis 2024
před 2 r.
Kvartální
Please find enclosed herewith unaudited financial results and limited review report of the Company for quarter ended 30th June, 24
9. srp 2024
před 2 r.
Výroční
Annual Report FY2024
26. čvc 2024
před 2 r.
Výroční
Pl. find enclosed Audited Financial results for quarter and year ended 31st march 24
29. kvě 2024
před 2 r.
Kvartální
Copy of Financial Results and LRR is enclosed herewith
9. úno 2024
před 3 r.
2023
Kvartální
Please find attached herewith copy of unaudited financial results and limited review of the Statutory Auditors is enclosed herewith
7. lis 2023
před 3 r.
Kvartální
Kindly refer to our intimation letter dated 31st July 23 pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (LODR) Reg, 2015. We are enclosing ....
10. srp 2023
před 3 r.
Výroční
Annual Report FY2023
14. čvc 2023
před 3 r.
Výroční
In continuation of our letter dated 9th May, 2023 and pursuant to Regulation 30 read with Regulation 33 of the SEBI LODR Regulations, the Board of Directors of the Company, at its meeting ....
19. kvě 2023
před 3 r.
Kvartální
In continuation of our letter dated 24th January, 2023 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure ....
10. úno 2023
před 4 r.
2022
Kvartální
Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed disclosure on a consolidated basis, for the half year ....
25. lis 2022
před 4 r.
Kvartální
In continuation of our letter dated 25th July, 2022 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure ....
5. srp 2022
před 4 r.
Výroční
Annual Report FY2022
11. čvc 2022
před 4 r.
Výroční
In continuation of our letter dated 28th April, 2022 and pursuant to Regulation 30 read with Regulation 33 of the SEBI LODR (''Listing Regulations'') the Board of Directors of the Company, ....
13. kvě 2022
před 4 r.
Kvartální
In continuation of our letter dated 24th January, 2022 and pursuant to Regulation 30 read with Regulation 33 and Regulation 42 of the Securities and Exchange Board of India (Listing Obligations ....
4. úno 2022
před 5 r.
2021
Kvartální
In continuation of our letter dated 02nd November, 2021 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure ....
12. lis 2021
před 5 r.
Kvartální
In continuation of our letter dated 26th July, 2021 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure ....
6. srp 2021
před 5 r.
Výroční
Annual Report FY2021
16. čvc 2021
před 5 r.
Výroční
continuation of our letter dated 14th May, 2021 and pursuant to Regulation 30 read with Regulation 33 of the SEBI LODR (''Listing Regulations'') the Board of Directors of the Company, at ....
25. kvě 2021
před 5 r.
Kvartální
In continuation of our letter dated 27th January, 2021 and pursuant to Regulation 30 read with Regulation 33 and Regulation 42 of the Securities and Exchange Board of India (Listing Obligations ....
5. úno 2021
před 6 r.
2020
Kvartální
In continuation of our letter dated 28th October, 2020 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure ....
6. lis 2020
před 6 r.
Kvartální
In continuation of our letter dated 27th July, 2020 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure ....
7. srp 2020
před 6 r.
Výroční
Annual Report FY2020
16. čvc 2020
před 6 r.
Výroční
In continuation of our letter dated 26th May, 2020 and pursuant to Regulation 30 read with Regulation 33 of the SEBI LODR (''Listing Regulations'') the Board of Directors of the Company, ....
5. čvn 2020
před 6 r.
Kvartální
In continuation of our letter dated 29th January, 2020 and pursuant to Regulation 30 read with Regulation 33 of the SEBI (LODR) Regulations, 2015 (''Listing Regulations'') the Board of ....
7. úno 2020
před 7 r.
2019
Kvartální
In continuation of our letter dated 18th October, 2019 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and ....
11. lis 2019
před 7 r.
Kvartální
In continuation of our letter dated 1st August, 2019 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure ....
12. srp 2019
před 7 r.
Výroční
Annual Report FY2019
30. čvc 2019
před 7 r.
Výroční
The Board of Directors at its meeting held today i.e. 30th May, 2019, has, inter alia: 1. approved the Standalone and Consolidated Audited Financial Statements of the Company for ....
30. kvě 2019
před 7 r.
Kvartální
The Board of Directors of the Company, at its meeting held today, i.e. 8th February, 2019 inter alia, has: a. Approved the Standalone and Consolidated Unaudited Financial Results for ....
8. úno 2019
před 8 r.
2018
Kvartální
In continuation of our letter dated 23rd October, 2018 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure ....
2. lis 2018
před 8 r.
Kvartální
In continuation of our letter dated 31st July, 2018 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure ....
10. srp 2018
před 8 r.
Výroční
The Board of Directors at its meeting held today i.e. 30th May, 2018, has, inter alia: 1. approved the Standalone and Consolidated Audited Financial Statements of the Company for the ....
30. kvě 2018
před 8 r.
Kvartální
The Board of Directors of the Company, at its meeting held today, i.e. 9th February, 2018 inter alia, has: a. Approved the Standalone and Consolidated Unaudited Financial Results ....
9. úno 2018
před 9 r.
2017
Kvartální
In continuation of our letter dated 1st November, 2017 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure ....
10. lis 2017
před 9 r.
Kvartální
In continuation of our letter dated 27th July, 2017 and pursuant to Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure ....
11. srp 2017
před 9 r.
Kvartální
Alkem Laboratories Ltd has informed BSE about : 1. Result Press Release for the period ended December 31, 2016 2. Result Presentation for the period ended December 31, 2016
10. úno 2017
před 10 r.
2016
Kvartální
Alkem Laboratories Ltd has informed BSE about : 1. Standalone Financial Results for the period ended September 30, 2016 2. Consolidated Financial Results for the period ended ....
11. lis 2016
před 10 r.
Kvartální
Alkem Laboratories Ltd has informed BSE about : 1. Standalone Financial Results for the period ended June 30, 2016 2. Consolidated Financial Results for the period ended June 30, 2016 ....
12. srp 2016
před 10 r.
Výroční
Alkem Laboratories Ltd has informed BSE about : 1. Standalone Financial Results for the period ended March 31, 2016 2. Consolidated Financial Results for the period ended ....
27. kvě 2016
před 10 r.
Kvartální
Alkem Laboratories Ltd has informed BSE about : 1. Standalone Financial Results for the period ended December 31, 2015 2. Consolidated Financial Results for the period ended ....
12. úno 2016
před 11 r.
Pro zvolenou kategorii nemáme žádné dokumenty.
